A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
This is a single arm, open-label, dose escalation, PK expansion and efficacy expansion study of phase I. The purpose of this study is to assess the tolerability, safety, pharmacokinetics and immunogenicity of SHR-A1811 and preliminary anti-tumor efficacy in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.
创建时间：
2021-03-15
